Premarket Briefing — Wednesday 2026-06-17 (US Eastern · FOMC DAY)
Run context: pre-market, ~09:00 ET, FOMC decision 2:00 PM ET + Warsh first press conf 2:30 PM ET. May Retail Sales 8:30 ET. LZB conf call 8:30 ET. Your daily briefing, brought to you by SignalDeck.liv
⚠ Macro context — FOMC day, two fresh-EP prints + first-in-class biotech catalyst
Today is THE day. Three time stamps to know:
8:30 AM ET — May Retail Sales release. LZB conference call. JBL conference call.
2:00 PM ET — Fed Funds rate decision + updated SEP + dot plot. 97% probability of hold at 3.50-3.75%.
2:30 PM ET — Warsh’s first post-meeting press conference. The new chair has advocated “less-is-more” forward guidance — increased volatility expected.
The signal everyone’s watching: with May CPI +4.2% YoY hot, the consensus is that the single projected rate cut from March’s SEP gets eliminated. A neutral-to-hawkish Warsh tone could move markets harder than the rate decision itself.
The market gave back some of Monday’s Iran-deal rip yesterday (S&P +0.13%, Nasdaq flat, but semis SMH −4.81%). That’s pre-FOMC profit-taking on the structural-thesis basket (MU/WDC/STX/SNDK). The R10.1 cohort-cohesion precondition (R14.17 candidate from yesterday) failed — CRDO got crushed −7.80% Day 4 of its R10.1 window because the cohort sold off mid-window, not because of CRDO-specific weakness.
Iran reality check: the 6/15 deal was a 14-point interim agreement. As of today, Strait of Hormuz commercial shipping is still disrupted (electronic interference at Bandar Abbas since 6/13), VLCC Gulf-to-China freight rates surged 24%, vessels still avoiding the Arabian Gulf. The de-escalation thesis is partially right but tempo is slower than the tape priced last week. Marine Shipping cohort (GNK) is the counter-narrative trade.
At a glance — fresh earnings-window prints
LZB STRONG⭐ · Gap +18.20% · EP-γ 77 · Furnishings cohort · Q4 EPS $1.26 vs $0.82 (+54% beat), Rev $570M slight miss, op margin 7.2% GAAP / 9.9% adj — pre-call, full conviction lands at 8:30 ET commentary
JBL qualitative-STRONG-borderline · Gap +5.46% · mechanical SKIP (8% gap gate) · Q3 EPS $3.16 non-GAAP, Rev $8.8B beat, AI-infra outlook raised — R14.12 artifact: qualitative cleanest setup pending 9:30 ET vol confirmation
At a glance — non-earnings movers (catalyst identified)
QURE news_driven · Gap +71.17% · rVol 34.58 · FDA accepted 3-year Phase I/II as primary basis for BLA on AMT-130 Huntington’s disease gene therapy — first-in-class regulatory unlock, BLA submission Q3, high conviction
GNK news_driven · Gap +5.74% · Marine Shipping · Strait of Hormuz freight rates +24%, vessels avoiding Gulf · Iran-tension-still-real counter-narrative, medium conviction
ACMR news_driven · Gap +8.03% · Semi Equipment · Roth Capital PT $70→$100, $150M cap raise priced, 65% YoY new orders, Hong Kong secondary listing planned · medium-high conviction (cap raise dilution partial offset)
AEHR sector_sympathy · Gap +7.79% · Semi Equipment continuation in the 6/11 R10.1 cohort that broke down yesterday — do not chase, wait for FOMC
BHVN sector_sympathy · Gap +9.18% · rVol 0.52 (light) · Biotech sympathy with QURE FDA pathway news, no own catalyst until Phase 2 results 7/1 — low
EOSE continuation · Gap +5.60% · yesterday’s pick D1 follow-through, banked 6/16 — already in book
WOLF sympathy_bounce · Gap +5.37% · yesterday’s D1 −8.33% bouncing — fade per yesterday’s exit-by-FOMC plan
ASTS sector_sympathy · Gap +5.35% · SpaceX IPO sympathy basket continuation — already in active catalyst, low add value
CPA sector_sympathy · Gap +6.02% · rVol 0.02 (dead) · Airlines Iran-deal beneficiary, retail-only, skip
CAPR, AKTS sector_sympathy · biotech low-vol sympathy with QURE — skip
⚠ SKIP SMCI · governance blacklist
⚠ SKIP QUBT · governance blacklist
⚠ SKIP PACS · governance blacklist
The cleanest setup on the board is QURE if you trade biotech — FDA accepted the 3-year Phase I/II analysis as the primary basis for the AMT-130 BLA in Huntington’s disease. That’s a first-in-class regulatory unlock for a disease with ZERO approved disease-modifying treatments. The +71% premarket on rVol 34.58 reflects the market repricing for accelerated approval. BLA submission Q3 2026. But the right play is to wait until 9:30 ET — pre-market biotech gaps on regulatory news routinely fade 20-30 points by mid-morning when fast-money exits. Size a starter at the open, not the gap.
The cleanest fresh-EP is LZB. Q4 +54% EPS beat is a real fundamentals confirmation; the slight revenue miss is offset by 9.9% adjusted operating margin (significant YoY improvement). EP-γ 77 STRONG⭐ from score-ticker is conservative — N-Score capped at 5 because the conference call doesn’t start until 8:30 ET. If the 8:30 ET call confirms forward-year guide raised, this re-scores to STRONG⭐⭐ within an hour.
JBL is the qualitative-strongest setup that fails the mechanical 8% gap gate. AI-infra contract manufacturer Q3 beat with revenue surprise +6.48%, EPS surprise +7.25%, and the company explicitly raised full-year AI-revenue outlook. This is the ORCL capex sympathy basket extending one more node down the supply chain. The 8% gap gate is a known mechanical artifact (R14.12 family) — when fresh-EP beats post in pre-market with gap 5-7%, the institutional flow shows up at 9:30 ET in vol expansion, not in the pre-market gap magnitude. Treat as qualitative STRONG-borderline pending 9:30 ET vol confirmation.
The Top Calls
LZB — La-Z-Boy · STRONG⭐ · EP-γ 77
Today’s catalyst: Q4 FY2026 earnings print AMC yesterday. EPS $1.26 vs $0.82 estimate (+54% beat), revenue $570M ($4.6M miss), operating margin improved to 7.2% GAAP / 9.9% adjusted. AH +12.66% reversal yesterday → premarket +18.20% today. Conference call 8:30 ET this morning (commentary will trigger STRONG⭐ → STRONG⭐⭐ re-rate IF forward guide raised).
Last earnings recap: Q3 print on 2026-02 was muted (R14-class “decent print muted reaction” archetype). Q4 +54% beat reverses that pattern hard.
Framework: fresh_ep, EP-γ 77 = mechanical STRONG⭐ tag, pre-call narrative still incomplete
Conviction: HIGH on the print; PENDING on the call. The 9.9% adjusted operating margin = real margin expansion, not a one-quarter fluke. Furnishings cohort historically pro-cyclical; if Warsh prints dovish dot-plot, LZB extends.
Trade plan: DO NOT enter on the pre-market +18% gap. Wait for 8:30 ET call. If forward guide raised, OR-breakout entry at 9:30 on vol >2x. Stop under premarket low. Partials at +1R. Trail rest under 9-EMA daily. Multi-week structural hold IF the call confirms.
JBL — Jabil · qualitative STRONG-borderline (mechanical SKIP)
Today’s catalyst: Q3 FY2026 earnings print this morning premarket. EPS $3.16 non-GAAP vs $2.94 estimate (+7.25% beat), revenue $8.8B (+6.48% beat). Full-year AI-related revenue outlook raised “meaningfully higher.” End-to-end AI systems integration story — compute + networking + power + advanced cooling for hyperscalers. Conference call 8:30 ET.
Framework: fresh_ep with R14.12-class mechanical gap-gate artifact (gap 5.46% < 8% gate triggers automatic SKIP in score-ticker). The qualitative thesis is STRONG-borderline despite the mechanical tag.
Conviction: HIGH qualitatively. Mega-cap quality ($41.8B mcap), structural AI-infra exposure, clean both-side beat. The “8% gap gate” is the wrong filter for a mega-cap that institutionally takes hours to fill — the open-vol confirmation gate at 9:30 ET is the right one.
Trade plan: DO NOT enter pre-market. At 9:30 ET, if rel-vol exceeds 2.0x and price holds the premarket gap, OR-breakout entry. If vol is light, skip. The trade either works as a multi-day structural-thesis continuation (ORCL capex Day 5 extension via the contract-manufacturer node) or it fades into the FOMC dead-tape. Position-sized smaller than LZB given the mechanical SKIP signal.
The Other Catalysts
QURE — uniQure · news_driven · regulatory unlock
Today’s catalyst: FDA Type B meeting result announced 6/17 morning. FDA accepted that the 3-year analysis from the AMT-130 Phase I/II study will be the primary basis of a BLA for accelerated approval in Huntington’s disease. BLA submission planned Q3 2026. This is a CRITICAL reversal of the March 2026 FDA position that demanded a randomized, sham-surgery-controlled study.
Framework: news_driven, first-in-class regulatory unlock
Conviction: HIGH on the catalyst quality (Huntington’s disease has zero approved disease-modifying treatments; AMT-130 would be first-in-class on accelerated approval); MEDIUM on entry timing (+71% premarket biotech gaps routinely fade 20-30 points by 10:30 ET when fast-money exits).
Trade plan: DO NOT chase the +71% premarket gap. Wait for 9:30 ET 30-min candle close. If price holds above the gap mid-point AND rel-vol stays >5x, OR-breakout entry. If chops to VWAP, pullback entry only. Aggressive partials at +1R given the inherent fade risk on regulatory-news gaps. Multi-quarter structural hold thesis intact IF BLA gets accepted Q3 — but trade only the trade-able portion of the move, not the structural one.
GNK — Genco Shipping · news_driven · Iran-counter-narrative
Today’s catalyst: Marine Shipping cohort lifted by Strait of Hormuz disruption that has NOT resolved despite the 6/15 Iran “deal.” Electronic interference at Bandar Abbas since 6/13. VLCC Gulf-to-China freight rates surged 24% to $1.67/barrel. Major maritime insurers withdrew war-risk coverage in late February; that has not been restored. Vessels still avoiding the Arabian Gulf. Approximately 22,500 mariners stranded on 1,550+ vessels per May data.
Framework: news_driven, geopolitical-tension-still-real
Conviction: MEDIUM. The catalyst is real (freight rates objectively up), but GNK is a small-cap ($1.08B mcap) with high beta and limited fleet exposure to Gulf routes specifically. The cleaner play might be the larger Asian shipping ETF basket (out of scope for this scan).
Trade plan: Position-light. The trade reverses fast if Iran ratifies the deal Friday in Switzerland and Hormuz traffic resumes. Stop tight under premarket low. Take partials at +1R. Exit fully if any Iran-deal-resolution headline crosses Friday/Monday.
ACMR — ACM Research · news_driven · analyst PT + cap raise
Today’s catalyst: Roth Capital PT raise $70→$100 (buy reiterated). $150M direct offering at $52 priced (about 2.88M shares). 65% YoY new orders growth, reaffirmed 2026 revenue guidance. Planned Hong Kong secondary listing.
Framework: news_driven, analyst_action + capital event
Conviction: MEDIUM. Multiple positive catalysts stacked; the $150M cap raise dilution offsets some upside. Semi-equipment cohort got slammed −4.81% yesterday — ACMR bucking the cohort sell-off is institutional-flow confirmation.
Trade plan: Open-vol gate at 9:30 ET. If rVol >2x and price holds premarket gap, scale-in 50%. Take partials at +1R. Trail under 9-EMA daily. The Hong Kong listing news suggests multi-week thesis but FOMC reaction Wednesday afternoon is the immediate gate.
The Quiet Beats
The 6/11 R10.1 second-entry window is BROKEN on the semi cluster. Do not re-enter CRDO/LRCX/AMAT/KLAC/ICHR/PDFS today — yesterday’s SMH −4.81% violated the R10.1 cohort-cohesion precondition (R14.17 candidate). The framework expects cohort stability through Days 4-7; that assumption failed. Wait for the cohort to reset above the 21-day MA before fresh-entry decisions.
The new R10.1 candidate is RXT (yesterday’s premarket pick at +4.99% D0). RXT R10.1 absorption window opens Monday 6/22 (Day 4) and closes Thursday 6/25 (Day 7). The AMD-30MW definitive agreement provides structural anchor; if RXT consolidates Wed-Fri post-FOMC above the 6/16 close on declining volume, the second-entry signal fires next week.
WDC continuation watch: day-3 of the structural ORCL capex sympathy trade. RS 98.9, week +31.55%, month +41.30% — RSI 73.46 is starting to extend. Today’s gap is muted; expect mean-reversion pressure into FOMC unless Warsh prints decisively dovish. Take partials at the open if you haven’t already; trail rest.
Yesterday’s Lessons
6/15 picks D1 outcomes filled — 7/11 directionally positive. ALHC +4.15% (defensive thesis worked), WDC +4.22% (storage cycle intact), STX +1.23%, TRIP +1.99%, AU +1.78%, BKNG +0.62%, AMRX +0.06% on the green side. MU −6.18% (profit-take after +10.85% D0, predicted), CRDO −7.80% (R10.1 cohort-cohesion failure), WOLF −8.33% (squeeze unwind as planned), ARCO −1.08%.
6/16 picks D0 outcomes — 3/4 positive. PURR +7.49%, EOSE +6.74%, RXT +4.99%, OLN −5.89% (merger reversal as planned).
R14.17 (cohort-cohesion precondition for R10.1) banked PRELIMINARY — CRDO Day 4 violation. Instance #1 of 5 needed for PROMOTED.
R14.18 (FQ-weighted top-3 escalation) banked PRELIMINARY — ALHC FQ 27 outperformed ARHS FQ 10 / CWH FQ 7 on D1. Velocity-only selection is suboptimal when cohort context is unclear. Instance #1 of 5 needed.
R14.16 (rVol >10x premarket on non-EP catalyst) candidate from 6/16 — RXT rVol 16.58 → D0 +4.99%. Today: QURE rVol 34.58 (highest premarket rVol of the year). The rule’s first 2 instances now logged.
The Read
Best risk-adjusted today: LZB if 8:30 ET call confirms raised forward guide. EP-γ 77 STRONG⭐, +54% EPS beat, op margin expansion — clean fundamentals story independent of FOMC outcome. Defensive consumer cyclical with rate-sensitivity = wins on dovish, holds on hawkish.
Best speculative single-name: QURE if you trade biotech regulatory catalysts. First-in-class FDA pathway = real catalyst quality. But trade only the portion you can size for a 30-point gap-fade — full move is not capturable.
Best AI-infra continuation: JBL if 9:30 ET vol confirms institutional flow. Mega-cap quality, structural ORCL-capex node, both-side Q3 beat. Don’t be fooled by the mechanical SKIP — the gap-gate is the wrong filter here.
Best multi-day compounder: WDC continuation with trailing stops. Don’t add at these levels; manage existing position. The structural thesis is intact through next earnings cycle.
Don’t chase tomorrow morning: any name in the 6/11 semi R10.1 cluster (CRDO/LRCX/AMAT/KLAC/ICHR/PDFS). Wait for cohort reset. ASTS/CPA/CAPR/AKTS — sympathy beta without institutional flow. WOLF bouncing is dead-cat, not re-entry.
Lesson banking watch:
R14.16 (rVol >10x premarket non-EP catalyst → D0 returns) — 2 instances now (RXT 6/16, QURE 6/17). Need 3 more.
R14.17 (R10.1 cohort-cohesion precondition) — 1 instance (CRDO 6/16). Need 4 more.
R14.18 (FQ-weighted top-3 escalation) — 1 instance (ALHC vs ARHS 6/16). Need 4 more.
R14.19 candidate — “When a fresh-EP fails the 8% gap-gate but has a both-side beat (eps_surprise >5% AND rev_surprise >5%) AND mega-cap (>$20B mcap), the qualitative-STRONG-borderline classification with 9:30 ET vol gate outperforms the mechanical SKIP on D1.” JBL today is instance #1. Need 4 more.
The trade-of-the-day positioning: LZB long pending call + small starter QURE + JBL on vol-gate confirmation. Everything else is wait-for-FOMC.
Pending review carryover
6/16 picks D1 due today (RXT/EOSE/PURR/OLN) — backfill at EOD sync tonight
6/15 picks D3 due tomorrow 6/18 — MU/WDC/STX/WOLF/TRIP/AU + ALHC/CRDO/ARCO/BKNG/AMRX
NAVN D5 due today (6/17) — final D5 reading
ENHA still 29d+ overdue — formally MISS at next outcome closure
Not financial advice. SignalDeck publishes daily Episodic Pivot signals at SignalDeck.live. 7-day free trial.